{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:36:27Z","timestamp":1777876587011,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neonatal-Perinatal Medicine"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the use of laser therapy as the current treatment for retinopathy of prematurity (ROP), the administration of ranibizumab is recognized as a promising alternative treatment for ROP despite the current use of laser therapy. Therefore, this systematic review aimed to systematically analyze the effectiveness of different ranibizumab dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search of PubMed, Cochrane, and ScienceDirect was conducted for studies including infants with ROP, using intravitreal injection of ranibizumab (IVR) as primary monotherapy, and reporting ROP regression and recurrence. All studies were required to be written in English-language and published in the last ten years. The selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of ten studies were reviewed, including three randomized controlled trials, five retrospectives, and two case series. Furthermore, 549 patients and 867 eyes in the treatment group were evaluated, examining various stages of ROP and different therapeutic methods. All studies reported ROP regression, ranging from 68.9% to 100%, while 80% reported ROP recurrence following IVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravitreal injections of ranibizumab were effective in improving ROP outcomes. Meanwhile, lower doses of IVR provided comparable therapeutic benefits to the higher dose, potentially with fewer side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/19345798251353790","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T02:00:26Z","timestamp":1751508026000},"page":"511-518","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the appropriate intravitreal ranibizumab dose for retinopathy of prematurity: A systematic review"],"prefix":"10.1177","volume":"18","author":[{"given":"S","family":"Salsabila","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Diponegoro University, Semarang, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SA","family":"Nabilah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5682-9633","authenticated-orcid":false,"given":"J","family":"Jutamulia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Trisakti University, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Blindness and vision impairment","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Blindness and vision impairment. Geneva: WHO, 2023. [cited 2024 Sep 9]. Available from. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment"},{"key":"e_1_3_3_3_2","first-page":"193","volume-title":"Basic and clinical science course","author":"Kim JS","year":"2024","unstructured":"Kim JS, Fawzi A, Kovach JL, et al. Retinopathy of prematurity. In: Rapuano CJ, Stout JT, McCannel CA (eds). Basic and clinical science course. San Francisco: American Academy of Ophthalmology, 2024, pp. 193\u2013213."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.031"},{"issue":"4","key":"e_1_3_3_5_2","first-page":"471e479","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106(4): 471e479.","journal-title":"Arch Ophthalmol"},{"key":"e_1_3_3_6_2","first-page":"233","article-title":"Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good WV","year":"2004","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102: 233\u2013250.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000578"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.03.018"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000380"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001173"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.20150090"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838"},{"issue":"7","key":"e_1_3_3_16_2","first-page":"e63712","article-title":"Comparison of intravitreal ranibizumab and laser photocoagulation in the treatment of type I retinopathy of prematurity in Malaysia: a one-year follow-up study","volume":"16","author":"Wardati HJ","year":"2024","unstructured":"Wardati HJ, Khadijah M, Nurul-Farhana M, et al. Comparison of intravitreal ranibizumab and laser photocoagulation in the treatment of type I retinopathy of prematurity in Malaysia: a one-year follow-up study. Cureus 2024; 16(7): e63712.","journal-title":"Cureus"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0001-7"},{"key":"e_1_3_3_18_2","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells G","year":"2021","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute, 2021. [cited 2024 Sep 2]. Available from. https:\/\/www.ohri.ca\/\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_3_19_2","first-page":"1","article-title":"Rob 2: a revised tool for assessing the risk of bias in randomized trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. Rob 2: a revised tool for assessing the risk of bias in randomized trials. BMJ 2019; 366: 1\u20138.","journal-title":"BMJ"},{"key":"e_1_3_3_20_2","volume-title":"Checklist for case series","author":"Joanna Briggs Institute","year":"2021","unstructured":"Joanna Briggs Institute. Checklist for case series. Adelaide: JBI, 2021. [cited 2024 Sep 2]. Available from. https:\/\/jbi.global\/sites\/default\/files\/2021-10\/Checklist_for_Case_Series.docx"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15199"},{"issue":"5","key":"e_1_3_3_22_2","first-page":"e2022319","article-title":"Retrospective observational studies: lights and shadows for medical writers","volume":"93","author":"Sanctis VD","year":"2022","unstructured":"Sanctis VD, Soliman AT, Daar S, et al. Retrospective observational studies: lights and shadows for medical writers. Acta Biomed 2022; 93(5): e2022319.","journal-title":"Acta Biomed"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002663"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001209"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.05.10"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000500310"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118812266"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02489-6"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305252"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14852"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06486-x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1055813"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.911095"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0685-6"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2015.01.009"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.01.014"}],"container-title":["Journal of Neonatal-Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19345798251353790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19345798251353790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19345798251353790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:27:09Z","timestamp":1777588029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19345798251353790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/19345798251353790"],"URL":"https:\/\/doi.org\/10.1177\/19345798251353790","relation":{},"ISSN":["1934-5798","1878-4429"],"issn-type":[{"value":"1934-5798","type":"print"},{"value":"1878-4429","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}